According to CoinMeta, ZaiDing Medicine (09688.HK) announced that its total revenue for the third quarter of 2026 was $108.2 million, compared to $116.1 million in the same period of 2025. The net product revenue for the third quarter of 2026 was $107.6 million, while in 2025 it was $115.4 million. Net product revenue increased by 2% quarter-on-quarter, mainly due to the success of NuZaiLe (benefiting from improved market coverage and penetration rates) and Tenuameline Trisclonamine (launched in June 2026). However, this increase was partially offset by a decline in revenue from tumor electrotherapy due to changes in the competitive landscape in the glioblastoma market. The net loss for the third quarter of 2026 was $46.1 million, resulting in a loss of $0.04 per common share attributable to common shareholders ($0.41 per American Depository Receipt ADS). In the same period of 2025, the net loss was $36 million, with a loss of $0.03 per common share ($0.33 per ADS). The increase in net loss was primarily due to an impairment of inventories amounting to $13.6 million in 2026.